Wedbush Securities Inc. trimmed its holdings in Eli Lilly and Co (NYSE:LLY) by 7.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,724 shares of the company’s stock after selling 906 shares during the period. Wedbush Securities Inc.’s holdings in Eli Lilly and were worth $990,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also made changes to their positions in the company. Pathstone Family Office LLC lifted its position in shares of Eli Lilly and by 100.0% in the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after acquiring an additional 29 shares in the last quarter. Vantage Financial Partners Ltd. Inc. purchased a new position in shares of Eli Lilly and in the second quarter valued at about $494,000. Gradient Investments LLC purchased a new position in shares of Eli Lilly and in the fourth quarter valued at about $103,000. Acrospire Investment Management LLC lifted its position in shares of Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares in the last quarter. Finally, MPS Loria Financial Planners LLC purchased a new position in shares of Eli Lilly and in the second quarter valued at about $128,000. Institutional investors and hedge funds own 75.71% of the company’s stock.
Shares of Eli Lilly and Co (NYSE LLY) opened at $77.40 on Tuesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Co has a 52 week low of $73.69 and a 52 week high of $89.09. The firm has a market capitalization of $86,950.00, a P/E ratio of 49.05, a price-to-earnings-growth ratio of 1.47 and a beta of 0.23.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The company had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. During the same period in the previous year, the firm posted $0.95 earnings per share. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. equities analysts predict that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.91%. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s payout ratio is presently 139.75%.
In other Eli Lilly and news, insider Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.09, for a total transaction of $72,981.00. Following the sale, the insider now directly owns 4,130 shares of the company’s stock, valued at $334,901.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the sale, the insider now directly owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Insiders have sold 259,610 shares of company stock worth $22,727,406 over the last three months. 0.20% of the stock is currently owned by insiders.
Several equities analysts have recently commented on LLY shares. Leerink Swann boosted their price objective on Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, October 24th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective on the stock in a research report on Thursday, October 26th. Berenberg Bank restated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research report on Thursday, October 26th. Finally, Morgan Stanley lifted their target price on Eli Lilly and from $86.00 to $90.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 21st. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $92.02.
WARNING: “Eli Lilly and Co (LLY) Shares Sold by Wedbush Securities Inc.” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/20/eli-lilly-and-co-lly-shares-sold-by-wedbush-securities-inc.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.